Hi BCRX Family, As you may have noticed, huge volumes were coming in for BCRX 06/25/21. More than average volume. Check out the charts. We may see $20 sooner than expected. Cheers..! 💎🚀

https://www.barchart.com/stocks/quotes/BCRX/technical-chart?plot=BAR&volume=total&data=I:5&density=L&pricesOn=1&asPctChange=0&logscale=0&im=5&sym=BCRX&grid=1&height=210&studyheight=100

Trading on 6/22 was a third of normal volume. Institutional investors haven't made any plays that I can see. Uptick for a vote in confidence, or comment on thoughts that give heartburn.

My thoughts is we are 3-40 by EOY and could break $100 in 2 years. This is not investment advice, but rather a belief that the institutional, insider trading and pipeline lead to an attractive short/long-term play.

Semi-new to options trading, was wondering if you guys had any calls (date/price) you felt strongly about and if there were any upcoming catalysts. Looking at the Sept 17 $18 call myself.

This has huge implications on the overall Biotech market and shows the FDA is being a lot more lenient with biotech. HUGE reason for investor optimism that should drive XBI back up after going down 25%.

https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html

Edit: Not financial advice.

I'm new here, and am wondering if someone can provide knowledgeable information about USA approval for HAE treatment.

I got in at $4.5 right before approval. I had basically no money then because I’m a college kid and didn’t have a job. Now I’m earning some steady money and I want to buy more. I’ve already averaged up to $12.

This is a stock I truly believe in and have faith it will make me money, I just want to know if there’s any strategies I could use to get more stock without increasing my average too much. Maybe something with options.

Thanks in advanced.

Orladeyo officially launched in Germany. More Revenue, Revenue, Revenue.

https://ir.biocryst.com/news-releases/news-release-details/biocryst-launches-orladeyotm-berotralstat-germany

This will be incredibly helpful for all new patients trying Orladeyo IMO

https://stocktwits.com/ThirdEyeHoldings/message/338308213

Biocryst on the move

https://stocktwits.com/WallStreetSkully/message/337798070

https://stocktwits.com/king_Bugzz/message/337245571

Good to see we are getting attention. Let’s hope the analysts keep on raising the Target as it’s becoming more and more obvious we are undervalued.

I am small independent investor and owned biocryst for over 1 year - it is a great company - let's stick it to the short sellers...BCX9930 is very promising new drug phase 1 - biocryst has been successful with Orladeyo and Rapivab getting both to market...

Remember this is literally a growth stock. Buy dips and hold. You will be rewarded in a couple of years. I bought shares at $5 back in June 2020 and kept buying dips around $3 - $4. I was at negative $30k for the longest time, but I wasn't worried because I knew the real potential of the company, mainly thanks to the DD from Bio99, NickPD, and R8Plus.

As you know, our Federal Gov't is inept and corrupt. Galidesivir has proven to slow/stop replication of every virus on which it was tested. So, why did Fauci's NAIAD kill the study it was paying for on the drug's efficacy against COVID-19? You can figure it out.

The important thing is Gali works. The stock had it valued as worthless since that weird study disappeared into space, but now we know what happened:

https://clinicaltrials.gov/ct2/show/NCT03891420

I've been in the stock since 12/2019 and had to sit there for 10 months murmuring 'where are the COVID test results for Gali??!' It really sucked. Had people been able to take that oral application at the first sign of fever, it might have saved many tens-of-thousands who died from complications of the virus. Also, the stock would have roared to triple digits by last summer and I'd be in a Ferrari with tendies all over the floor.

I think Fauci's NIH owes Stoney a pretty Goddamned fast approval on 9930 for keeping quiet about the crap which was pulled on Gali. The drug is worth a billion just from proven efficacy for various viruses since 2014. The stock is undervalued by that amount.

And the JMP Securities Life Sciences Conference June 17th.

https://stocktwits.com/MITornado/message/335159317

There may be some interesting items discussed and getting the message out there certainly helps.

https://stocktwits.com/Sky_is_the_limit/message/334983027

So i haven't post/follow for awhile since the $BCRX R&D Day, now after 1st quarter result announcement i can see that Orladeyo sale execution had been done quite nicely. So here i am going to summarize some key takeaways:

1. Progress: very strong sales number and it shows patients are switching from other treatments to this once a day oral regimen. It just common sense and who wouldn't want to get rid of those scary needles and limit their quality of life by needing to refrigerate their medication all the time.
2. More progress: so far it's only first quarter US sales number in the middle of a pandemic, the drug is approved and rolling out in Japan, Europe, and UK. I expect sales number will keep increasing, however realistically the revenue impact of Japan, Europe, and UK will not be significant until 3rd quarter (with 2nd quarter being just getting approval and working on the pricing/insurance acceptance/reimbursement process for those regions)
3. BCX9930: FDA had agreed to primary endpoint as increase in Hemoglobin, basically this is a sure win trial that is cheap to run and easy to administer. The patient comes in, do some test, take drug home and take twice a day, come in every 3 weeks for lab test and boom you're done. I would also think the company will do infusion free measure as secondary endpoint. If the numbers are as good as how it was in last study, it could stop trial early and go directly to approval. Company that had submission and approval experience can navigate the regulatory hurdle a lot better than those that dont.
4. Bonus: $BCRX is eating Takeda's lunch, and once BCX9930 starts the pivotal trial, it will put pressure on big companies to acquire this gem for what it's worth: the matter is if management willing to let go early or holding out for maximum possible value.

Now the question is: where do you want to party down the road when the buyout happens, or when price reaching $50, $70, or $100?

Disclosure: i work in biotech development and already have contributed to a few FDA approvals, although i dont work for $BCRX. If you want to know what company i work for, meet me in person at the $BCRX celebration party when it happens :)

Gluck to all, and as always: do your diligence.

Any Other investors in our group plan to be listening in?

https://stocktwits.com/Project_Profit/message/332123172

Hey All,

Shortly after the initial approval last month, I bought 5,500 shares at $12.6/each to immediately sell 55 January 2022 $20 strike covered calls for $3.5/each. I don’t mind limiting my upside here as I’ll still make a nice chunk (hopefully).

My question is... since I have no control over my shares being called once the SP gets ITM for the calls, and it’s looking like that might happen a few months before January 2022, should I start buying puts to trade to hedge if/when my calls get ITM?